Collaboration with MedPharm Ltd. delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections.
New formulations support a growing pipeline alongside lead drug asset, XF-73, currently in Phase 2b development with data anticipated in mid-2020.
Please see Destiny Pharma press release here